Centers for Disease Control and Prevention. (2021). Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recommendations and Reports, 70(4), 1-187.
[2]
Brunham, R. C., & Rey-Ladino, J. (2005). Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nature Reviews Immunology, 5(2), 149-161.
[3]
Haggerty, C. L., Gottlieb, S. L., Taylor, B. D., Low, N., Xu, F., & Ness, R. B. (2010). Risk of sequelae after Chlamydia trachomatis genital infection in women. Journal of Infectious Diseases, 201(S2), S134-S155.
[4]
Sweet, R. L., & Gibbs, R. S. (2019). Infectious Diseases of the Female Genital Tract (6th ed.). Lippincott Williams & Wilkins.
[5]
World Health Organization. (2021). Global Health Sector Strategy on Sexually Transmitted Infections 2016-2021. WHO Press.
[6]
Workowski, K. A., & Bolan, G. A. (2015). Sexually transmitted diseases treatment guidelines, 2015. MMWR Recommendations and Reports, 64(RR-03), 1-137.
[7]
Kreisel, K., Torrone, E., Bernstein, K., Hong, J., & Gorwitz, R. (2017). Prevalence of Pelvic Inflammatory Disease in Sexually Experienced Women of Reproductive Age — United States, 2013–2014. MMWR Morbidity and Mortality Weekly Report, 66(3), 80-83.
[8]
Mitchell, C., Prabhu, M., & Totten, P. A. (2013). Innate immune cellular responses to Chlamydia trachomatis infection. In Chlamydia (pp. 69-100). Springer.